Vericel (NASDAQ:VCEL) Issues Earnings Results

Vericel (NASDAQ:VCEL) posted its quarterly earnings data on Thursday. The biotechnology company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.12, Zacks reports. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $64.57 million. Vericel had a return on equity of 2.47% and a net margin of 2.85%.The company’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.02) EPS. Vericel updated its FY 2025 guidance to EPS.

Vericel Price Performance

Vericel stock traded up $0.21 during trading hours on Friday, hitting $38.96. The company had a trading volume of 531,288 shares, compared to its average volume of 566,964. The firm’s fifty day moving average is $33.73 and its 200-day moving average is $37.74. Vericel has a fifty-two week low of $29.24 and a fifty-two week high of $63.00. The firm has a market capitalization of $1.97 billion, a P/E ratio of 324.78 and a beta of 1.41.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d+)” rating on shares of Vericel in a research report on Wednesday, October 8th. Zacks Research raised Vericel from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. BTIG Research cut Vericel from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 17th. Canaccord Genuity Group reduced their price objective on shares of Vericel from $61.00 to $58.00 and set a “buy” rating for the company in a research note on Friday, August 1st. Finally, Truist Financial decreased their target price on shares of Vericel from $46.00 to $41.00 and set a “buy” rating for the company in a report on Wednesday, October 15th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Vericel presently has an average rating of “Moderate Buy” and a consensus price target of $58.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in shares of Vericel by 22.9% during the 2nd quarter. Bank of America Corp DE now owns 438,228 shares of the biotechnology company’s stock valued at $18,647,000 after buying an additional 81,600 shares during the last quarter. Raymond James Financial Inc. raised its position in Vericel by 20.6% during the second quarter. Raymond James Financial Inc. now owns 432,440 shares of the biotechnology company’s stock valued at $18,400,000 after acquiring an additional 73,779 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Vericel by 13.6% in the first quarter. Goldman Sachs Group Inc. now owns 371,486 shares of the biotechnology company’s stock valued at $16,576,000 after acquiring an additional 44,333 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Vericel by 2.8% in the second quarter. Ameriprise Financial Inc. now owns 365,054 shares of the biotechnology company’s stock valued at $15,533,000 after acquiring an additional 9,822 shares during the last quarter. Finally, Qube Research & Technologies Ltd grew its position in Vericel by 5.1% in the second quarter. Qube Research & Technologies Ltd now owns 277,253 shares of the biotechnology company’s stock worth $11,797,000 after acquiring an additional 13,422 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.